A pilot study of botulinum toxin A for male chronic pelvic pain syndrome

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 1, 2011, Pages 72-76

  Gottsch, Henry P ^a   Yang, Claire C ^a   Berger, Richard E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Botulinum toxin; bulbospongiosus; chronic pelvic pain syndrome; chronic prostatitis; randomized controlled trial; transperineal

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BULBOSPONGIOSUS MUSCLE; CHRONIC PROSTATITIS SYMPTOM INDEX; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FECES INCONTINENCE; FOLLOW UP; GLOBAL RESPONSE ASSESSMENT; HUMAN; INJECTION SITE REACTION; MALE; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; PERINEUM; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKELETAL MUSCLE; SYMPTOMATOLOGY; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PELVIC PAIN; PERINEUM; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 79951608164     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2010.529820     Document Type: Article

References (18)

1. Hetrick DC, Ciol MA, Rothman I, Turner JA, Frest M, Berger RE. Musculoskel et al dysfunction in men with chronic pelvic pain syndrome type III: a case-control study. J Urol 2003;170:828-31. (Pubitemid 36999568)
2. Berger RE, Ciol MA, Rothman I, Turner JA. Pelvic tenderness is not limited to the prostate in chronic prostatitis/chronic pelvic pain syndrome (CPPS) type IIIA and IIIB: comparison of men with and without CP/CPPS. BMC Urol 2007;7:7.
3. Fitz Gerald MP, Anderson RU, Potts J, Payne CK, Peters KM, Clemens JQ, et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009;182:570-80.
4. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005;174:155-60. (Pubitemid 40825701)
5. Coelho A, Dinis P, Pinto R, Gorgal T, Silva C, Silva A, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2009; Dec. 29 [Epub].
6. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;28:72:1473-8.
7. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-7.
8. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005;118:170-5. (Pubitemid 41566596)
9. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-83.
10. Hetrick DC, Glazer H, Liu YW, Turner JA, Frest M, Berger RE. Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case-control study. Neurourol Urodyn 2006;25:46-9. (Pubitemid 43050207)
11. Zermann D, Ishigooka M, Schubert J, Schmidt RA. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000;38:393-9.
12. Bschleipfer T, Wagenlehner FM, Weidner W. Intraprostatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Urologe A 2007;46:1030-2. (Pubitemid 47459056)
13. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369-75. (Pubitemid 29434343)
14. Propert KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006;15:299-305. (Pubitemid 43226935)
15. Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008;180:742-8.
16. Baranowski AP, Abrams P, Berger RE, Buffington CA, de C Williams AC, Hanno P, et al. Urogenital pain - time to accept a new approach to phenotyping and, as a consequence, management. Eur Urol 2008;53:33-6. (Pubitemid 350166743)
17. Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A. Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. Urology 2009;73:987-92.
18. Pezzone MA, Liang R, Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 2005;128:1953-64. (Pubitemid 40824705)